Anavex Life Sciences Corp (AVXL)

[XenaLives]

AD/PDTM 2017 FORUM ON TRANSLATIONAL RESEARCH IN DRUG DISCOVERY FOR AD: A PLETHORA OF TARGETS: WHICH IS THE BEST, IS THERE "A BEST ONE"?

Thursday, March 30; 14:45-16:45: HALL A

Moderator: Ezio Giacobini, University of Geneva Medical School Hospitals, Switzerland and Bengt Winblad, Karolinska Institute, Sweden

Susan Catalano, Founder & CSO, Cognition Therapeutics Inc, USA: DIRECT DISPLACEMENT OF Aß OLIGOMERS FOR EFFFECTIVE ALZHEIMER'S DIEASE MODIFICATION: CLINICAL EXPERIENCE WITH CT1812

David Elmaleh, Scientific Founder and Chairman?, AZ Therapeutics, USA

Teiji Kimura, Chief Discovery Officer, Eisai, Japan: COMBINATION THERAPY ERA WILL EMERGE FOR ALZHEIMER'S DISEASE MODIFICATION IN NEAR FUTURE. CAN BIOMARKERS SUGGEST THE BEST OPTION TO HETEROGENEOUS PATIENTS?

Christopher U. Missling, President & CEO, Anavex Life Sciences Corp., USA: RESTORING CELLULAR HOMEOSTASIS: DEVELOPING TARGETED THERAPIES FOR THE TREATMENT OF NEURODEVELOPMENTAL AND NEURODEGENERATIVE DISEASES UNDER THE PRECISION MEDICINE PARADIGM

??Martin Tolar, Founder, President & CEO, Alzheon, USA: ALZ-801: EFFICIENT ALZHEIMER'S DISEASE MODIFICATION BY PREVENTING FORMATION OF TOXIC AMYLOID AGGREGATES

Lon S. Schneider, Keck School of Medicine of the University of Southern California, USA??: A PLETHORA OF BEST TARGETS OR WINNERS' CURSES? UNTURNED STONES AND WHY TRIALS FAIL

Bengt Winblad, Karolinska Institute, Sweden: WHAT IS THE DRIVING FORCE BEHIND CLINICAL TRIALS JUMPING OVER PHASE II;INCREASED RISK FOR FAILED PHASE III?

http://adpd2017.kenes.com/scientific-information/forum-discussions#.WLWSnvkrLIU